2020
DOI: 10.5152/dir.2019.19063
|View full text |Cite
|
Sign up to set email alerts
|

Introducing PHIL (precipitating hydrophobic injectable liquid) – a new embolic agent for the body interventional radiologist

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(18 citation statements)
references
References 7 publications
0
12
0
Order By: Relevance
“…Squid (Squid-Peri, Emboflu, Gland, Switzerland) is a relatively new non-adhesive liquid embolic agent which has mainly also been used in the cerebral district [ 12 ] with some recent application in the abdominal district [ 13 ]. PHIL (MicroVention, Tustin, CA, USA) and Easyx (MicroVention, Tustin, CA, USA) are the latest liquid embolic agents to appear on the market for which there is not already solid literature available [ 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…Squid (Squid-Peri, Emboflu, Gland, Switzerland) is a relatively new non-adhesive liquid embolic agent which has mainly also been used in the cerebral district [ 12 ] with some recent application in the abdominal district [ 13 ]. PHIL (MicroVention, Tustin, CA, USA) and Easyx (MicroVention, Tustin, CA, USA) are the latest liquid embolic agents to appear on the market for which there is not already solid literature available [ 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…PHIL is an established treatment option in interventional neuroradiology for the embolization of cerebral and spinal arteriovenous malformations and dural fistulae. It is also increasingly being used in body intervention [5] . Liquid embolic agents such as PHIL have several advantages over traditional coiling and particulate-based embolization techniques: they solidify when injected into the vasculature, providing a superior mould of their target area's geometry compared to coiling; the processes of solidification and occlusion are independent of the patient's physiology, allowing their use in patients with coagulopathies and patients receiving anti–coagulation treatment; and they are considered less likely to fragment and migrate than particulate-based embolic materials.…”
Section: Discussionmentioning
confidence: 99%
“…A variety of agents have been used in the management of auricular AVMs, including ethanol, 11,17 N–butyl cyanoacrylate (NBCA), 29,44,45 Onyx, 8,44 precipitating hydrophobic injectable liquid (PHIL), 46 polyvinyl alcohol (PVA) particles, 35 coils, 10,17,42,47 and gelatin sponge 12,48 . The characteristics, drawbacks, and clinical applications of these agents are summarized in Table 4 7,10,11,16,17,29,42,44,47–66 . Among these embolic agents, ethanol is the only agent that can provide permanent embolization of AVMs, but its risk and high technical requirements limit its wide application 11,17,67 .…”
Section: Discussionmentioning
confidence: 99%
“…12,48 The characteristics, drawbacks, and clinical applications of these agents are summarized in Table 4. 7,10,11,16,17,29,42,44,[47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66] Among these embolic agents, ethanol is the only agent that can provide permanent embolization of AVMs, but its risk and high technical requirements limit its wide application. 11,17,67 Other embolic agents are generally used for hemostasis of acute bleeding and palliative embolization when used alone, due to the possibility of vascular recanalization.…”
Section: Surgical Resection Combined With Endovascular Treatmentmentioning
confidence: 99%